{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031340","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.198239+00:00","generated_at":"2026-05-31T10:16:31.271855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate","bullets":["Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.","Prioritized EB-003, a non-hallucinogenic neuroplastogenic molecule, as lead development candidate.","Preclinical data confirms oral bioavailability and brain exposure of EB-003; IND filing expected Q3 2025.","Signed licensing agreement with Aries Science & Technology for radiation dermatitis product; non-binding term sheets for joint disease and cancer treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031340","json":"https://secwatch.observer/filing/0001493152-24-031340.json","markdown":"https://secwatch.observer/filing/0001493152-24-031340.md","text":"https://secwatch.observer/filing/0001493152-24-031340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224031340/0001493152-24-031340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224031340/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:16:31.271855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}